GSK – Discontinuation of Blenrep® (belantamab mafodotin-blmf)

- On November 22, 2022, GSK announced the market withdrawal of Blenrep (belantamab mafodotin-blmf) following the request of the FDA. This request was based on the previously announced outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations.
    - Clinical Services did not identify any prescription claims for members on Blenrep therapy thus notifications will not be sent.
- Blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
    - This indication was approved under accelerated approval based on response rate.
- As part of GSK's efforts to ensure physicians and patients are supported during this important time, patients already enrolled in the Blenrep Risk Evaluation and Mitigation Strategy (REMS) program will have the option to enroll in a compassionate use program to continue to access treatment.
- Further information on how to enroll patients into the compassionate use program will be provided directly to REMS enrolled prescribers. Patients currently being treated with Blenrep should consult their healthcare provider.
- GSK continues to believe, based on the totality of data available from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) development program, that the benefit-risk profile of Blenrep remains favorable. Patients responding to Blenrep experienced durable clinical benefit, and safety remains consistent with the known safety profile.

Product Description	NDC#
Blenrep (belantamab mafodotin-blmf) 100 mg lyophilized powder in a single-dose vial	0173-0896-01